Research detection kit NG22305027

for thyroid cancerGNASfor BRAF mutations

Thyroid nodules can be found in various age groups. In the adult population, the incidence rate detected through physical examinations is approximately 5%-7%, while the incidence rate detected through ultrasound examination ranges from 20%-76%. Different pathological types of thyroid nodules (tumors) exhibit significant differences in their biological behavior. From benign thyroid adenomas and indeterminate thyroid nodules to thyroid carcinoma, these variations can have a profound impact on patient prognosis and treatment options. AUXILIARY EXAMINATION AND DIAGNOSIS Ultrasound: Ultrasound examination is simple and non-invasive, with high specificity and sensitivity for thyroid nodule detection. Cytopathology Diagnosis Report: The Bethesda System is used for the reporting of cytopathology diagnosis. Molecular Testing: To improve the accuracy and effectiveness of thyroid fine-needle aspiration (FNA) cytology diagnosis, molecular testing is recommended for III and IV category thyroid FNA specimens or Puncture eluent. DETECTED GENES This test adopts the high-throughput sequencing method and covers the genes related to the identification, prognosis and adjuvant treatment of thyroid tumors recommended in the NCCN guidelines, CSCO guidelines and expert consensus. DETECTION SIGNIFICANCE 1. Patients with thyroid nodules with uncertain results in US-FNA cytological diagnosis undergo testing to assist in the diagnosis of nodule benignity or malignancy. 2. Patients with DTC (Differentiated Thyroid Carcinoma) who are planning for surgical treatment, radioactive iodine therapy, or ablation therapy undergo testing to assess tumor recurrence risk